AveXis Inc (AVXS) Price Target Raised to $92.00 at Jefferies Group LLC

AveXis Inc (NASDAQ:AVXS) had its target price upped by Jefferies Group LLC from $79.00 to $92.00 in a research report sent to investors on Friday morning. They currently have a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. Chardan Capital reissued a buy rating and set a $100.00 price objective (up previously from $85.00) on shares of AveXis in a report on Tuesday, February 7th. Goldman Sachs Group Inc raised their price objective on shares of AveXis from $91.00 to $108.00 and gave the stock a buy rating in a report on Friday. Zacks Investment Research raised shares of AveXis from a sell rating to a hold rating in a report on Tuesday, February 14th. Finally, BMO Capital Markets reissued an outperform rating and set a $95.00 price objective (up previously from $85.00) on shares of AveXis in a report on Friday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. AveXis presently has a consensus rating of Buy and an average price target of $85.33.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ:AVXS) traded up 11.34% during trading on Friday, hitting $81.03. 3,384,076 shares of the company traded hands. The firm’s market cap is $2.24 billion. AveXis has a 52-week low of $20.51 and a 52-week high of $85.98. The company’s 50-day moving average is $62.69 and its 200 day moving average is $53.26.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, March 16th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by $0.12. During the same period in the prior year, the business earned ($1.82) EPS. On average, equities analysts anticipate that AveXis will post ($3.93) earnings per share for the current year.

Your IP Address:

A number of hedge funds have recently added to or reduced their stakes in AVXS. Pacad Investment Ltd. bought a new stake in AveXis during the fourth quarter worth $277,000. A.R.T. Advisors LLC boosted its stake in AveXis by 68.8% in the fourth quarter. A.R.T. Advisors LLC now owns 10,800 shares of the company’s stock worth $515,000 after buying an additional 4,400 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in AveXis during the fourth quarter worth $640,000. Norges Bank bought a new stake in AveXis during the fourth quarter worth $1,193,000. Finally, GAM Holding AG bought a new stake in AveXis during the third quarter worth $1,212,000. 68.31% of the stock is currently owned by institutional investors.

About AveXis

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

5 Day Chart for NASDAQ:AVXS

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/avexis-inc-avxs-price-target-raised-to-92-00-at-jefferies-group-llc/1709247.html

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *